Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
Go back to Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy| (NASDAQ: PRAX) | Delayed: 303.39 +21.08 (7.47%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $282.31 | 52 Week High | $ | |||
| Open | $292.56 | 52 Week Low | $ | |||
| Day High | $305.00 | P/E | N/A | |||
| Day Low | $285.00 | EPS | $ | |||
| Volume | 657,226 | |||||
